Abstract

Eli Lilly and Company is partnering with ProQR Therapeutics to develop up to five RNA-editing therapies for genetic diseases of the liver and nervous system. ProQR is one of several firms designing oligonucleotides that recruit a human enzyme called ADAR to make single-nucleotide changes in RNA. In August, Roche partnered with Shape Therapeutics to develop similar RNA-editing systems. ProQR will get $50 million up front and milestone payments of up to $1.25 billion.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call